Literature DB >> 27645764

Prevalence and Predictors of Early Discontinuation of Dual-Antiplatelet Therapy After Drug-Eluting Stent Implantation in Korean Population.

Mi Hee Cho1, Dong Wook Shin2, Jae Moon Yun1, Joong Hyun Shin1, Seung Pyo Lee3, Hyejin Lee1, Yoo Kyoung Lim1, Eun Ha Kim1, Hyun Kyoung Kim1.   

Abstract

The administration of antiplatelet drugs for months after a drug-eluting stent implantation is critical in decreasing the risk of complications, and premature discontinuation of antiplatelet therapy before the recommended period is the most important predictor for late complications. Therefore, we investigated the prevalence and associated factors of premature discontinuation of antiplatelet therapy in patients in Korea. This retrospective cohort study was conducted using the Korean National Health Insurance Service-National Sample Cohort data. Patients who were treated with dual-antiplatelet therapy (DAPT) were identified with medication prescription data. The Kaplan-Meier failure time plot was used to illustrate the cumulative probability of treatment discontinuation. Cox regression analysis was conducted to compare predictors of early discontinuation of DAPT. The characteristics of the early discontinuation group were not significantly different from the guideline concordance group, except for a higher prevalence of disability and a lower rate of chronic kidney disease. In a Cox regression model, the presence of hypertension was identified as a negative predictor of early discontinuation, and disability was not a statistically significant predictor. The prevalence of early discontinuation was 31.0% and seems to be significantly higher than those reported from prospective studies, which may more accurately reflect the real-world situation. In conclusion, physicians should make more effort to educate patients on the risk associated with premature discontinuation of antiplatelet therapy after percutaneous coronary intervention with drug-eluting stent, and further studies investigating the reasons for nonadherence of DAPT are needed to improve DAPT compliance.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27645764     DOI: 10.1016/j.amjcard.2016.07.073

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  3 in total

1.  Rationale and design of the Web-basEd soCial media tecHnology to improvement in Adherence to dual anTiplatelet Therapy following Drug-Eluting Stent Implantation (WECHAT): protocol for a randomised controlled study.

Authors:  Guo-Li Sun; Li Lei; Liwei Liu; Jin Liu; Yibo He; Zhaodong Guo; Xiaohua Dai; Lihao He; Shi-Qun Chen; Yan Liang; Jianfeng Ye; Yunzhao Hu; Guoqin Chen; Ji-Yan Chen; Yong Liu
Journal:  BMJ Open       Date:  2020-01-07       Impact factor: 2.692

2.  Multifaceted Intervention to Improve P2Y12 Inhibitor Adherence After Percutaneous Coronary Intervention: A Stepped Wedge Trial.

Authors:  P Michael Ho; Colin I O'Donnell; Marina McCreight; Anthony A Bavry; Hayden B Bosworth; Saket Girotra; P Michael Grossman; Christian Helfrich; Faisal Latif; David Lu; Michael Matheny; Kreton Mavromatis; Jose Ortiz; Amitabh Parashar; Devona M Ratliff; Gary K Grunwald; Michael Gillette; Hani Jneid
Journal:  J Am Heart Assoc       Date:  2022-06-29       Impact factor: 6.106

3.  Outcomes in relation to antithrombotic therapy among patients with atrial fibrillation after percutaneous coronary intervention.

Authors:  Jiesuck Park; Eue-Keun Choi; Kyung-Do Han; Bongseong Kim; You-Jung Choi; So-Ryoung Lee; Jeehoon Kang; Myung-Jin Cha; Kyung Woo Park; Seil Oh; Gregory Y H Lip
Journal:  PLoS One       Date:  2020-10-15       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.